The Effect of Fenofibrate on the Levels of High Sensitivity C‐Reactive Protein in Dyslipidemic Obese Patients

References

• Benzaquen L R, Yu H, Rifai N. High sensitivity C‐reactive protein: an emerging role in cardiovascular risk assessment. Crit Rev Clin Lab Sci 2002; 39: 459–497
   PubMed Web of Science ®Google Scholar
• Wellen K E, Hotamisligil G S. Obesity‐induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785–1788
   PubMed Web of Science ®Google Scholar
• Blake G J, Ridker P M. Inflammatory bio‐markers and cardiovascular risk prediction. J Intern Med 2002; 252: 283–294
   PubMed Web of Science ®Google Scholar
• Ridker P M. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999; 10: S9–S12
   PubMedGoogle Scholar
• Ridker P M. High‐sensitivity C‐reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003; 92: 17K–22K
   PubMed Web of Science ®Google Scholar
• Futterman L G, Lemberg L. High sensitivity C‐reactive protein is the most effective prognostic measurement of acute coronary events. Am J Crit Care 2002; 11: 482–486
   PubMed Web of Science ®Google Scholar
• Rifai N, Ridker P M. High‐sensitivity C‐reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47: 403–411
   PubMed Web of Science ®Google Scholar
• Ridker P M, Buring J E, Cook N R, Rifai N. C‐reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8‐year follow‐up of 14719 initially healthy American women. Circulation 2003; 107: 391–397
   PubMed Web of Science ®Google Scholar
• Wang T D, Chen W J, Lin J W, Cheng C C, Chen M F, Lee Y T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003; 170: 315–323
   PubMed Web of Science ®Google Scholar
• Kuller L H, Tracy R P, Shaten J, Meilahn E N. Relation of C‐reactive protein and coronary heart disease in the MRFIT nested case‐control study. Multiple risk factor intervention trial. Am J Epidemiol 1996; 144: 537–547
   PubMed Web of Science ®Google Scholar
• Tracy R P, Lemaitre R N, Psaty B M, Ives D G, Evans R W, Cushman M, Meilahn E N, Kuller L H. Relationship of C‐reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol 1997; 17: 1121–1127
   PubMed Web of Science ®Google Scholar
• Winegar D A, Brown P J, Wilkison W O, Lewis M C, Ott R J, Tong W O, Brown H R, Lehmann J M, Kliewer S A, Plunket K D, Way J M, Bodkin N L, Hansen B C. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res 2001; 42: 1543–1551
   PubMed Web of Science ®Google Scholar
• Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000; 247: 563–569
   PubMed Web of Science ®Google Scholar
• Evans M, Anderson R A, Graham J, Ellis G R, Morris K, Davies S, Jackson S K, Lewis M J, Frenneaux M P, Rees A. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000; 18(101)1773–1779
   Google Scholar
• Watts G F, Dimmitt S B. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 1999; 10: 561–574
   PubMed Web of Science ®Google Scholar
• Rizos E, Kostoula A, Elisaf M, Mikhailidis D P. Effect of ciprofibrate on C‐reactive protein and fibrinogen levels. Angiology 2002; 53: 273–277
   PubMed Web of Science ®Google Scholar
• Baron R B. Lipid abnormalities. Current Medical Diagnosis and Treatment40th ed., L M Tiernay, S J McPce, M A Papadakus. McGraw‐Hill, Lange Medical Books, New York 2001; 1208–1221
   Google Scholar
• Ferrannini E, Haffner S M, Mitchell B D, Stem M P. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416–422
   PubMed Web of Science ®Google Scholar
• Vidal H. Obesity and inflammation: the adipocytokines. Ann Endocrinol (Paris) 2003; 64: S40–S44
   Web of Science ®Google Scholar
• Ridker P M, Glynn R J, Hennekens C H. C‐reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007–2011
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088–2093
   PubMed Web of Science ®Google Scholar
• Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002; 18: 269–276
   PubMed Web of Science ®Google Scholar
• Zhao S P, Ye H J, Zhou H N, Nie S, Li Q Z. Gemfibrozil reduces release of tumor necrosis factor‐alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease. Clin Chim Acta 2003; 332: 61–67
   PubMed Web of Science ®Google Scholar
• Chen Y E, Fu M, Zhang J, Zhu X, Lin Y, Akinbami M A, Song Q. Peroxisome proliferator‐activated receptors and the cardiovascular system. Vitam Horm 2003; 66: 157–188
   PubMed Web of Science ®Google Scholar
• Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra I P, Delerive P, Fadel A, Chinetti G, Fruchart J C, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth‐muscle cells is inhibited by PPARalpha but not by PPAR gamma activators. Nature 1998; 393: 790–793
   PubMed Web of Science ®Google Scholar
• Lee H J, Choi S S, Park M K, An Y J, Seo S Y, Kim M C, Hong S H, Hwang T H, Kang D Y, Garber A J, Kim D K. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 2002; 296: 293–299
   PubMed Web of Science ®Google Scholar
• Idzior‐Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wojcik J, Zarnecki A, Blane G. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000; 30: 871–878
   PubMed Web of Science ®Google Scholar